Health Care • Biotechnology: Pharmaceutical Preparations
$40.15 ▲ +0.32
(+0.80%)
MKT CAP: $1.30B • VOL: 400.7K
52W L $14 52W H $50
ROARABLE / RQD
D- • 43/100
PIOTROSKI
2 / 9
LBRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | $0 | $0 |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$25.2M | -$63.1M |
| EBITDA (Normalized) | — | — |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$35.2M | -$53.1M |
| Capital Expenditures (CapEx) | $52.0K | $769.0K |
| Free Cash Flow (FCF) | -$35.3M | -$53.8M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | — | — |
| Cash & Short-Term Equivalents | $250.2M | $23.0M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $301.3M | -$94.6M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LBRX.